vaccinex.com (VCNX): חוב להון עצמי

The price trend illustrated in this chart demonstrates a debt-to-equity ratio of 0.00, highlighting a severe liquidity shortage and forced share issuances by Vaccinex, Inc. (VCNX). Vaccinex, Inc. (VCNX) is developing immune therapies for oncology and dementia while facing the threat of failed tests for Huntington's disease. Growth potential is based on licensing patents to global partners to generate royalties.

Developing innovative antibodies to combat neurodegeneration requires colossal clinical trial expenditures, making the analysis of the debt-to-equity ratio critical for assessing the financial stability of Vaccinex, Inc. (VCNX). This ratio compares total liabilities to shareholders' equity, allowing investors to determine the business's level of dependence on creditors and the bankruptcy risks in the absence of strategic partnerships.